Psoriasis exacerbation after COVID-19 vaccines: A brief report of the reported cases.
Dermatol Ther
; : e15900, 2022 Oct 06.
Article
in English
| MEDLINE | ID: covidwho-2052397
ABSTRACT
Despite the significant reduction of both morbidity and mortality after the introduction of many vaccines against COVID-19, recent reports indicated a worsening skin conditions in particular patients with psoriasis. We extracted the data of 51 patients from 19 papers. The mean age was 56.9 (SD = 16.2) years, with a male prevalence 45%. Of the 51 cases, vaccine types at which psoriasis flare occurred were as the following Pfizer vaccine (30), AstraZeneca (9), Moderna (8), Coronavac (2) Covishield (1), and Covaxin (1). Exacerbation was common in the second dose of Pfizer, AstraZeneca, Moderna, and Covishield vaccines. Moreover, the onset of psoriasis exacerbation was shorter after the second dose of Pfizer (mean = 12.8 [SD = 15.2]) and AstraZeneca (mean = 7.4 [SD = 3.6]) rather than the first dose of both vaccines, respectively (mean = 19.2 [SD = 21.3]) and (mean = 18.5 [SD = 10.7]).
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Observational study
Topics:
Vaccines
Language:
English
Journal:
Dermatol Ther
Journal subject:
Dermatology
Year:
2022
Document Type:
Article
Affiliation country:
Dth.15900
Similar
MEDLINE
...
LILACS
LIS